Immunocore Working With EMA On Novel TCR Therapy Filing
Executive Summary
While Immunocore is not giving details of what issues it still needs to address regarding its EU filing for tebentafusp, it said the drug is continuing to undergo an accelerated assessment by the CHMP.
You may also be interested in...
Idorsia’s Insomnia Drug Daridorexant Among 14 Hopefuls For EU Verdict
The European Medicines Agency will likely decide this week whether to recommend for pan-EU approval new treatments for insomnia, uveal melanoma, migraine and advanced prostate cancer.
BMS’ Cell Therapy For Lymphoma On Track For EU-Wide Approval
Several new drugs are now on track for an EU marketing authorization after getting the EMA’s thumbs up this week.
Immunocore Ready For First-Ever Launch After Kimmtrak’s US Approval
The median pre-discount cost of Kimmtrak – the first approved TCR therapy and the first drug cleared for metastatic uveal melanoma – is $430,000, but the company says payers see the product’s value.